We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Panel Detects Early Signs of Kidney Transplant Rejection

By LabMedica International staff writers
Posted on 12 Aug 2019
A team of European kidney transplantation researchers has developed and validated an mRNA-based gene set found in peripheral blood that can identify patients with symptoms of antibody-based kidney transplant rejection.

Antibody-mediated rejection, a leading cause of kidney transplantation failure, is currently diagnosed by histological assessment of invasive allograft biopsies. More...
Accurate non-invasive biomarkers are not available, and from 10 to 20% of rejections remain undetected, which leads to graft failure, reinitiation of dialysis, and the need for a repeat transplant.

To identify potential rejection biomarkers, investigators at KU Leuven (Belgium) and their collaborators performed a genome-wide study (GWAS) to identify differences in RNA molecules among 117 patients with and without kidney rejection symptoms following transplant. In the second phase of the study, the different molecules of an independent group of 183 patients were processed into a mathematical model. The final biomarker consists of eight RNA molecules that were measured with an RT-PCR technique. In the third phase, the biomarker was validated in 387 patients in four European academic hospitals.

Blood samples for the investigation were prospectively collected from participants in the BIOMARGIN study at time of renal allograft biopsies between June 2011 and August 2016. BIOMARGIN (Limoges, France) was a four-year European collaborative research project that began in March 2013. The consortium brought together 13 complementary partners, including three small and medium enterprises, one technology transfer / management company, five academic laboratories, and four university hospitals from four European Member States (France, Belgium, Germany, and Sweden).

Results obtained during the initial phase of the study served to identify an eight-gene assay (CXCL10, FCGR1A, FCGR1B, GBP1, GBP4, IL15, KLRC1, TIMP1) in blood samples from 49 cases with and 134 cases without antibody-mediated rejection. In the validation cohort, this eight-gene assay discriminated between 41 cases with and 346 cases without antibody-mediated rejection with good diagnostic accuracy. The diagnostic accuracy of the eight-gene assay was retained both at time of stable graft function and of graft dysfunction, within the first year and also later after transplantation.

"Rejection by HLA antibodies often has serious consequences," said senior author Dr. Maarten Naesens, professor of nephrology at KU Leuven. "Traditional tests for assessing the function of transplanted kidneys can often only identify rejection when it is already chronic and irreversible. Thanks to our biomarker, we can detect rejection much earlier and with a simple blood test. Because the test is less invasive, we will be able to test more often than with the current biopsies."

"In principle, our antibody rejection test has been sufficiently validated for commercialization," said Dr. Naesens. "This is the next and necessary step to be able to offer the test to patients. With the test, patients who have no rejection of antibodies will no longer have to undergo a biopsy. The biomarker will also help to detect rejection sooner and will support the search for better medicines against rejection by antibodies."

The eight-gene panel was described in the August 1, 2019, online edition of the journal EbioMedicine.

Related Links:
KU Leuven
BIOMARGIN


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.